Anacor Pharmaceuticals

Nasdaq

Biotech

AN2 upsizes IPO, teeing up bid to revitalize ex-GSK, Pfizer drug

AN2 has upsized its IPO, reeling in $69 million for a pivotal trial of an antibiotic it picked up from Pfizer’s Anacor.

Nick Paul Taylor Mar 25, 2022 8:45am

allergic conjunctivitis

Realm scraps eye drug after midphase flop, sinking stock

Mar 12, 2018 9:00am

Pfizer HQ

Pfizer pays $5.2B for eczema specialist Anacor

May 16, 2016 7:14am